OncoMatch/Clinical Trials/NCT07362979
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
Is NCT07362979 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including GP plus Toripalimab Induction chemotherapy+CCRT and TP plus Toripalimab Induction chemotherapy+CCRT for nasopharyngeal cancinoma (npc).
Treatment: GP plus Toripalimab Induction chemotherapy+CCRT · TP plus Toripalimab Induction chemotherapy+CCRT · TPC plus Toripalimab Induction chemotherapy+CCRT — This phase II randomized trial compares the efficacy and safety of Toripalimab combined with three different platinum-based induction chemotherapy regimens, sequentially followed by standard concurrent chemoradiotherapy, for the treatment of locally advanced nasopharyngeal carcinoma (NPC). The study is aimed to pick up the most effective platinum-based induction chemotherapy regimen plus Toripalimab for these patients which provides the most survival benefit.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage ANY T, N2-3, T4, N1 (AJCC 9th edition)
Excluded: Stage DISTANT METASTASIS (M1)
Stage Any T, N2-3 or T4, N1 (AJCC 9th edition staging), with no distant metastasis (M0). Patients with nasopharyngeal carcinoma presenting with recurrence or distant metastasis [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Prior history of radiotherapy
Cannot have received: systemic chemotherapy
Prior history of systemic chemotherapy
Cannot have received: immune checkpoint inhibitor (CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor)
Patients previously treated with immune checkpoint inhibitors (e.g., CTLA-4, PD-1, PD-L1 inhibitors)
Cannot have received: anticancer monoclonal antibody
Exception: within 4 weeks prior
Patients who have received high-dose glucocorticoids, anticancer monoclonal antibodies, or other immunosuppressive therapy within 4 weeks prior
Cannot have received: immunosuppressive therapy
Exception: within 4 weeks prior
Patients who have received high-dose glucocorticoids, anticancer monoclonal antibodies, or other immunosuppressive therapy within 4 weeks prior
Lab requirements
Blood counts
Hemoglobin (HGB) ≥ 90g/L, Absolute Neutrophil Count (ANC) ≥ 1.5×10^9/L, and Platelet (PLT) ≥ 100×10^9/L
Kidney function
Serum creatinine ≤ 1.5×ULN or calculated creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault formula)
Liver function
ALT and AST ≤ 2.5×ULN, total bilirubin ≤ 2.0×ULN, and serum albumin ≥ 30g/L
Adequate hematological function: Hemoglobin (HGB)≥90g/L, Absolute Neutrophil Count (ANC) ≥ 1.5*10^9/L, and Platele (PLT) ≥100*10^9/L. Adequate hepatic function: ALT and AST≤2.5*Upper Limit of Normal (ULN), total bilirubin ≤2.0*ULN, and serum albumin≥30g/L. Adequate renal function: Serum creatinine ≤ 1.5*ULN or calculated creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify